Arcus Biosciences, Inc.
RCUS NYSE· Pharmaceutical Preparations
Last close · Oct 26, 2026
$17.76
KIRA · Stoqly’s AI analyst, in plain words
- Arcus Biosciences, Inc. had $247M of revenue in fiscal 2025, down 4.3% on the year before. Over five years, revenue changed +25.9% a year on average.
- Its operating margin was −156.3%, down 28.4 pts: of every 100 in sales, about −156 is left after running the business.
- Arcus Biosciences, Inc. lost $353M in fiscal 2025.
- Free cash flow was −$484M in fiscal 2025, −196.0% of revenue.
- Arcus Biosciences, Inc. has $882M more cash than debt.
Market cap
$2.2B
P/E
—
Revenue
$247M
Net income
−$353M
Free cash flow
−$484M
Operating margin
−156.3%
Arcus Biosciences, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−4.3%
No. Sales fell 4.3% last year.
Does it make a profit?
−142.9%
No. It lost money last year.
Does profit turn into cash?
−196.0%
No. It spent more cash than it brought in.
How healthy are the accounts?
0 / 8
Weak. It passes 0 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Arcus Biosciences, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 25, 2026
- Legal name
- Arcus Biosciences, Inc.
- CIK
- 0001724521
Arcus Biosciences, Inc. · RCUS
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $383M | $112M | $117M | $258M | $247M |
| Revenue growth | 391.0% | −70.8% | 4.5% | 120.5% | −4.3% |
| Operating margin | 14.1% | −250.0% | −290.6% | −127.9% | −156.3% |
| Net income | $53.0M | −$267M | −$307M | −$283M | −$353M |
| Net margin | 13.8% | −238.4% | −262.4% | −109.7% | −142.9% |
| Diluted EPS | $0.71 | −$3.71 | −$4.15 | −$3.14 | −$3.29 |
| Cash | |||||
| Cash from operations | −$256M | $438M | −$306M | −$170M | −$482M |
| Capital expenditure | $26.0M | $6.0M | $24.0M | $6.0M | $2.0M |
| Free cash flow | −$282M | $432M | −$330M | −$176M | −$484M |
| FCF margin | −73.6% | 385.7% | −282.1% | −68.2% | −196.0% |
| Share count change | 35.0% | −2.7% | 2.8% | 21.8% | 19.2% |
| Debt and strength | |||||
| Cash and short-term investments | $499M | $1.0B | $759M | $978M | $981M |
| Debt incl. finance leases | — | — | $0.0M | $48.0M | $99.0M |
| Shareholders' equity | $842M | $657M | $462M | $485M | $631M |
| Current ratio | 7.6x | 5.5x | 4.5x | 4.5x | 4.4x |
| Interest coverage | — | −140.0x | −170.0x | −82.5x | −48.3x |
| Returns and quality | |||||
| Return on equity | 7.9% | −35.6% | −54.9% | −59.8% | −63.3% |
| Return on tangible equity | 6.3% | −40.6% | −66.5% | −58.4% | −55.9% |
| Piotroski F-score | 4 | 3 | 2 | 3 | 0 |
| Altman Z'' | 5.4 | 2.6 | 0.0 | 0.1 | −0.8 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$13.6M
7 insiders
Of sales under plans
100%
$13.6M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Arcus Biosciences, Inc. · RCUS
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $17.76 a share, the company is worth $2.2B.
Source: SEC EDGAR XBRL filings (CIK 0001724521). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.